Sanofi is taking the external route again to boost its early-stage pipeline by paying $125m upfront to Denali Therapeutics Inc. as part of a collaboration exploring neurological and inflammatory diseases.
The pact initially involves the development of two drugs that target receptor-interacting serine/threonine-protein kinase 1 (RIPK1), which regulates inflammation and...








